Clinical Trial Update: The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating apatinib plus cytokine-induced killer (CIK) cells as third-line therapy for advanced lung adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma

Drugs mentioned

• Apatinib (apatinib)
• CIK Cells

Snippet

Sponsor: The First People's Hospital of Changzhou | Conditions: Adenocarcinoma of Lung | Phase 2 | Status: ACTIVE_NOT_RECRUITING